Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Q: This release makes no mention of the costs of the drugs compared in this study, even though the drugs have been in use for years and are widely available. Since the study is a comparison of various treatments for this form of cancer, it seems relevant to offer a cost comparison as well as a comparison of efficacy. It appears that the high dose methotrexate is given over a 24-hour period, presumably in the hospital, while the standard methotrexate is given as a single dose. Also, the high dose methotrexate isfollowed by leucovorin administration while the standard dose is not. According to the site GoodRx, the cost for methotrexate in low-dose (2.5 mg) pill form averages out to about $50 for a month's supply. Newer, injectable variations of the drug cost upwards of $500 a month for the 25 mg dose. The release states that patients receiving high doses of the drug methotrexate "had a significantly better outcome, by 5 to 6 percent" than did patients receiving the current standard of care, which is gradually escalating doses of the drug. The release also explains that patients nine years old or younger who were also treated with a steroid called decadron (dexamethasone) forhalf as long as normal (14 versus 28 days) benefited from the treatment while patients 10 and older did not. We're not sure of the meaning behind these results as portrayed in the release. Which outcome was better by 5 or 6 percent? The study has several. Does that mean the relapse rate was reduced or is it the event free survival that was better? It would be more meaningful to readers if the release had included the actual relapse and event free survival rates for each group analyzed in terms most people can understand. For example: "relapse rates were 5 percent lower in Group X compared to Group Y." We'll give this category a satisfactory rating largely due to the release including information that patients 10 and older receiving dexamethasone "were at much higher risk for a debilitating bone condition called osteonecrosis," although we would have been happier if that greater risk would have been quantified. However, the published study explains that there were toxicity problems beyond that of dexamethasone and the release would have been stronger including that information as well. The release stated the study was randomized and controlled, and provides a broad overview of the study design, for which we give the release a borderline satisfactory under this criteria. However, these are thesuperficial results. On deeper delving into the study methodology, the statistical significances of the results were very close to notstatistically significant. This is due to their planned interim stopping of the treatment and the fact that they were looking at multiple outcomes in multiple groups. This release doesn't demonstrate disease-mongering. While the release does say that this clinical trial was run by the Children's Oncology Group, which is funded by the National Cancer Institute and the National Institutes of Health, it makes no mention of possible conflicts of interest. Compounding that is the fact that the published study says, "Disclosures provided by the authors are available with this article at www.jco.org," but that information is behind the journal's paywall for most readers, so it's unknown if there is, or is not, a conflict. It appears as though five of the authors (out of a total of about 20) have some conflicts of interest, mostly from several types of drug company payments. The release is comparing the efficacy of treatment regimens using different drugs so alternative treatmentsfor B-acute lymphoblastic leukemia are noted. The release makes clear at the end that the treatment of this disease is improving thanks to refinement of the use of existing drug treatments, meaning that they are readily available for patient use. The release suggests the study findings could change the way childhood leukemia is treated. Modifying existing treatments to enhance a patient's survival is certainly novel enough to warrant a release. There is no use of unjustifiable language in this release. However, the tone may be a bit overly optimistic given the study findings.

A: Relapses of childhood leukemia improve with high doses of common chemo drug
****
Q: Thirteen years ago, the Advisory Committee on Immunization Practices recommended hepatitis A shots for all U.S. children at age 1. On Thursday, the panel said the shots should be given to older children who weren't vaccinated earlier, including 14- to 18-year-olds who turned 1 before the recommendation was made. The panel also recommended the shots for every person with HIV. About 1.1 million Americans are estimated to have HIV, the virus that causes AIDS. People with HIV tend to develop more severe hepatitis A illnesses. U.S. hepatitis A infections and deaths have risen in the last two years, spurred by outbreaks among the homeless and drug users.

A: Health panel: Millions of US kids should get hepatitis shot.
****
Q: Under her leadership, the organization gained in membership, donor support and political clout but found itself in constant conflict with social conservatives for its role as the leading abortion provider in the United States. The organization provides a range of health services at clinics nationwide, including birth control, cancer screenings and tests for sexually transmitted diseases. Republicans in Congress tried repeatedly to cut off federal funding that helps subsidize Planned Parenthood's services to some patients, and several congressional committees investigated the organization's role in providing post-abortion fetal tissue to researchers. In a statement Friday, Richards said she would remain engaged in political activism ahead of the November elections. "There has never been a better moment to be an activist," said Richards, who was a featured speaker in Las Vegas at one of last weekend's largest women's marches. Richards, 60, is the daughter of former Texas Gov. Ann Richards. Before joining Planned Parenthood, she was a union organizer and deputy chief of staff to U.S. Rep. Nancy Pelosi, among other roles. Reaction to Richards' announcement reflected the divisive nature of the debate over Planned Parenthood's role. Pelosi, the House minority leader, hailed her as "a portrait of energy, intellect, and determination" whose impact transcended reproductive rights. "As an organizer, activist, and leader, Cecile has helped launch a nationwide movement to defend and advance women's rights, and in doing so, she has inspired countless women to march, vote, run, and win." Pelosi said. Anti-abortion activists seized the occasion to demonize Richards. Her legacy "is one of death and destruction," said Kristin Hawkins, president of Students for Life of America. "She leaves broken lives in her wake." Many of the key battles for Richards and Planned Parenthood were waged in Congress, where Republicans repeatedly, though unsuccessfully, sought ways to cut off its federal funding. GOP lawmakers also organized multiple investigative committees after anti-abortion activists released secretly recorded videos in 2015 that they said showed Planned Parenthood employees illegally selling fetal tissue for profit. Planned Parenthood emphatically denied that claim. Thus far there's been no formal finding by Congress of wrongdoing by the organization, but the dispute over the allegations is not settled. Justice Department officials confirmed in December that the department was considering investigations related to the transfer of fetal tissue. There was no immediate word of a possible successor to Richards. Planned Parenthood said it would be announcing future plans after a meeting of its board of directors next week. Planned Parenthood said Richards helped grow its base of supporters from 3 million to 11 million and build its donor base to its largest ever. She oversaw a notable expansion of services to LGBT people, including sharp increases in HIV testing and the provision of hormone therapy for transgender patients. Richards' resignation precedes the scheduled publication of her memoir, "Make Trouble," in April.

A:
Cecile Richards stepping down as Planned Parenthood leader.
****